Science
Two transcription factors reproduce the beneficial side of a 'Jekyll and Hyde' viral protein
Publication: Phys.org - latest science and technology news stories
Author: Not available in collected metadata
Source published: 16/11/2026, 20:40:04 UTC
Briefing created: 16/11/2026, 20:52:13 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 16/11/2026, 20:40:24 UTC.
Briefings
Scientists at Hiroshima University identified two transcription factors, Spi-B and IRF1, that enable the beneficial 'Dr. Jekyll' side of the Epstein-Barr virus LMP1 protein to activate CD8+ T cells. By expressing these factors together, researchers found tumor cells became more accessible to the immune system without the virus itself, offering a potential therapeutic strategy.
Key points
- Spi-B and IRF1 are two transcription factors that, when co-expressed, enhance the immune recognition of tumor cells by the Epstein-Barr virus LMP1 protein.
- The study utilized a method where the viral protein was removed, allowing the immune system to target the cells solely through the presence of the two transcription factors.
Context
This research addresses the dual nature of LMP1, which can promote cancer or spur antitumor immune responses. The findings provide a mechanism to harness the protective side of the virus for potential cancer treatments.
Limitations
The study relies on in vitro expression of transcription factors rather than clinical trials. Results are based on laboratory models and do not yet confirm efficacy in human patients.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 16/11/2026, 20:52:13 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeiexqjgvsjolaalen5lxg3drelqkuljdsjdutw6vwni6lxcjuckdqe